Zebra Biologics Inc.
- UEI
- MGBMJBJ59E65
- CAGE
- 7Z6E5
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- zebrabiologics.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Engineering a long-acting relaxin agonist to treat liver fibrosis - project summary/abstract relaxin is a… | National Institute of Diabetes and Digestive and Kidney Diseases | $926,124 | |
| Treatment of diabetic retinopathy with trkb agonist antibodies | National Eye Institute | $210,558 | |
| TRK agonist antibodies for the treatment of hearing loss | Defense Health Agency | $268,681 | |
| Discovery of trkc agonist antibodies for hearing loss | National Institute on Deafness and Other Communincation Disorders | $0 |
About Zebra Biologics Inc.
Zebra Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Through federal grants, Zebra Biologics conducts research and development activities related to engineering proteins and antibodies for the treatment of diseases involving tissue fibrosis, hearing loss, and vision loss.
Zebra Biologics has received federal grants from the National Institutes of Health and the Department of the Army to develop Trk agonist antibodies to treat hearing loss, TrkB agonist antibodies to treat diabetic retinopathy, and a long-acting relaxin agonist called H2-PIP to treat liver fibrosis. These grants were funded through NIH's National Institute on Deafness and Other Communication Disorders, National Eye Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and the Department of the Army Medical Command. The relaxin agonist grant aims to conduct pharmacokinetic, pharmacodynamic, and efficacy analyses in mouse models over a two-year period to potentially inform future clinical trials for fibrotic diseases. The Trk and TrkB agonist antibody grants focus on preclinical development and testing to treat sensorineural hearing loss and vision loss complications.
Quick answers
What is Zebra Biologics Inc.'s UEI?
Zebra Biologics Inc.'s Unique Entity ID (UEI) in SAM.gov is MGBMJBJ59E65.
What is Zebra Biologics Inc.'s CAGE code?
Zebra Biologics Inc.'s CAGE code is 7Z6E5.
What is Zebra Biologics Inc.'s primary NAICS code?
Zebra Biologics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Zebra Biologics Inc. registered in SAM.gov?
Zebra Biologics Inc.'s SAM.gov registration expired on October 21, 2025.
What is Zebra Biologics Inc.'s most recent federal award?
Zebra Biologics Inc.'s most recent federal grant award is Engineering a long-acting relaxin agonist to treat liver fibrosis - project summary/abstract relaxin is a… (R41DK131681), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 17, 2021.
On GovTribe
See Zebra Biologics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors